Keros Therapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2020 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Keros Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2020 to Q3 2024.
  • Keros Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 8.63 %, a 9.15% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 8.63 -0.87 -9.15% Sep 30, 2024
Q2 2024 8.93 +0.56 +6.69% Jun 30, 2024
Q1 2024 9.24 +1.33 +16.8% Mar 31, 2024
Q4 2023 9.75 +2.62 +36.7% Dec 31, 2023
Q3 2023 9.51 +3.99 +72.3% Sep 30, 2023
Q2 2023 8.37 +2.72 +48.1% Jun 30, 2023
Q1 2023 7.91 +3.24 +69.4% Mar 31, 2023
Q4 2022 7.13 +2.83 +65.7% Dec 31, 2022
Q3 2022 5.52 +1.75 +46.4% Sep 30, 2022
Q2 2022 5.65 +1.96 +53.1% Jun 30, 2022
Q1 2022 4.67 +0.37 +8.6% Mar 31, 2022
Q4 2021 4.31 -2.38 -35.6% Dec 31, 2021
Q3 2021 3.77 -12.4 -76.7% Sep 30, 2021
Q2 2021 3.69 Jun 30, 2021
Q1 2021 4.3 Mar 31, 2021
Q4 2020 6.68 Dec 31, 2020
Q3 2020 16.1 Sep 30, 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.